Please login to the form below

Not currently logged in
Email:
Password:

Vifor Pharma

This page shows the latest Vifor Pharma news and features for those working in and with pharma, biotech and healthcare.

Real-world data finds patients feel better on Entresto, says Novartis

Real-world data finds patients feel better on Entresto, says Novartis

Lokelma (sodium zirconium cyclosilicate or ZS-9) and Vifor Pharma’s Veltassa (patiromer) which “will be a particularly valuable addition to the clinic if efficacy can be confirmed in clinical trials”.

Latest news

  • AZ gets US approval for Veltassa rival Lokelma AZ gets US approval for Veltassa rival Lokelma

    AstraZeneca has picked up FDA approval for its hyperkalaemia treatment Lokelma, allowing it to compete head-to-head with rival Vifor Pharma on both sides of the Atlantic. ... AZ acquired Lokelma via the $2.7bn acquisition of ZS Pharma three years ago

  • AZ finally gets EU nod for Veltassa rival Lokelma AZ finally gets EU nod for Veltassa rival Lokelma

    challenge Vifor Pharma’s Veltassa (patiromer) which was approved in the EU last year and has been sold in the US since 2015. ... delaying approval and giving Vifor time to consolidate its position in the market.

  • Novartis and Bayer among backers for European big data project Novartis and Bayer among backers for European big data project

    Novartis, Bayer, Servier and Vifor Pharma are among those participating in BigData@Heart, a five-year, 19m project supported by the Innovative Medicines Initiative (IMI). ... Digital inspiration for pharma on mobile, social media, strategy, best practice,

  • Vifor wins European approval for Veltassa Vifor wins European approval for Veltassa

    The go-ahead is a significant milestone for Vifor Pharma Group - who acquired Veltassa from Relypsa - as it marks the drug’s first regulatory approval outside the US. ... Scott Garland, president of Relypsa, said: “We look forward to working with our

  • Pfizer gets FDA panel recommendation for biosimilar EPO Pfizer gets FDA panel recommendation for biosimilar EPO

    If approved it will also be sold by Vifor Pharma in the US dialysis market. ... Epogen shrank by a third last year thanks in part to switching of some patients to Amgen's long-acting ESA Aranesp (darbepoetin alfa) and competition from Roche/Vifor's

More from news
Approximately 3 fully matching, plus 8 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    Other pharma companies divesting assets this month include Janssen/J&J and Sanofi. ... In an expansion of their May 2016 licence, Vifor Pharma has gained additional territorial rights from ChemoCentryx to avacopan, a phase III oral inhibitor of the

  • Deal Watch July 2016 Deal Watch July 2016

    Celyad. $311m. $12.5m. Almirall. Patagonia. $28m. $3.5m. Petra Pharma. Sprint BioScience. ... Galenica, the Swiss healthcare company that is preparing itself for a split into two parts, Vifor Pharma (healthcare product development, manufacturing and

  • Deal Watch May 2016 Deal Watch May 2016

    The presence of the CRL on the books however did not deter Vifor Fresenius Medical Care Renal Pharma's decision to license Rayaldee [a vitamin D prohormone treatment] from OPKO paying ... 293. OPKO Health/ Vifor Fresenius. Licence. Rayaldee in EP, CA,

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • Hansa Medical poaches Vifor Pharma’s CEO Hansa Medical poaches Vifor Pharma’s CEO

    Tulstrup was most recently CEO of Swiss pharmaceutical group Vifor Pharma and prior to this he served as senior vice president, global franchise head at Shire. ... Additionally, Tulstrup has served as CEO of Santaris Pharma, now part of Roche, and in

  • Swiss biotech Inositec appoints new chief medical officer Swiss biotech Inositec appoints new chief medical officer

    Dr van Alphen joins from Roche, where he headed its operational excellence team and prior to this he was chief medical officer at Vifor Pharma, head of medical affairs Europe at

  • Galenica Group strengthens management team Galenica Group strengthens management team

    Appoints Stefan Schulze, Felix Burkhard and Jörg Kneubühler. Stefan Schulze has been appointed as chief operating officer and president of the executive committee of Vifor Pharma, part of the Switzerland-based ... We opted for these variant because of

  • Lupin appoints Thierry Volle president for EMEA Lupin appoints Thierry Volle president for EMEA

    He moves to the company from Vifor. Mumbai-based pharma company Lupin has appointed Thierry Volle to lead its Europe, Middle-East and Africa operations as president. ... He joins the firm from Vifor Pharma, where he was the head of EU and International

  • Verona names David Ebsworth as non-executive chairman Verona names David Ebsworth as non-executive chairman

    He joins from Vifor Pharma. Verona Pharma has appointed Dr David Ebsworth as its non-executive chairman of the board of directors. ... He most recently served as CEO at Vifor Pharma and was also named CEO of Galenica in 2011, continuing to be an adviser

More from appointments
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest from PMHub

  • IGNIFI

    Nike. Novartis. PGT Healthcare. Smith and Nephew. Theramex. Veriton Pharma. Vifor Pharma. ... Communicating with HCPs 101: we put ourselves in HCPs’ shoes to understand exactly what they want from pharma communications.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Tapping the potential of rare diseases: A journey into uncharted territory
...
The 2019 WHO essential medicine list: Narrowing the access gap to innovative cancer treatments
The essential medicine list (EML) contains treatments considered to be the most effective and safe in targeting global health concerns. On 9 July 2019, the World Health Organization (WHO) published...
NICE
Evolution or revolution: the latest review of NICE methods
By Leela Barham...

Infographics